



## King's Research Portal

DOI:

[10.1016/j.ymthe.2016.10.012](https://doi.org/10.1016/j.ymthe.2016.10.012)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Whilding, L. M., Parente Pereira, A. C., Zabinski, T., Davies, D. M., Petrovic, R., Kao, V., Saxena, S. A., Romain, A., Costa-Guerra, J. A., Violette, S., Itamochi, H., Ghaem-Maghami, S., Vallath, S., Marshall, J. F., & Maher, J. (2017). Targeting of aberrant v6 integrin expression in solid tumors using chimeric antigen receptor-engineered T-cells. *Molecular Therapy*, 25(1), 259-273. <https://doi.org/10.1016/j.ymthe.2016.10.012>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# **Targeting of aberrant $\alpha\text{v}\beta 6$ integrin expression in solid tumors using chimeric antigen receptor-engineered T-cells**

Lynsey M. Whilding<sup>1</sup>, Ana C Parente-Pereira<sup>1</sup>, Tomasz Zabinski<sup>1</sup>, David M. Davies<sup>1</sup>, Roseanna M.G. Petrovic<sup>1</sup>, Y. Vincent Kao<sup>1</sup>, Shobhit A. Saxena<sup>1</sup>, Alex Romain<sup>1</sup>, Jose A. Costa-Guerra<sup>1</sup>, Shelia Violette<sup>2</sup>, Hiroaki Itamochi<sup>3</sup>, Sadaf Ghaem-Maghami<sup>4</sup>, Sabari Vallath<sup>5</sup>, John F. Marshall<sup>5</sup>, John Maher<sup>1,6,7</sup>

<sup>1</sup>King's College London, King's Health Partners Integrated Cancer Centre and Division of Cancer Studies, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; <sup>2</sup>Biogen Idec Cambridge, MA 02142, USA; <sup>3</sup>Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, 020-8505, Japan; <sup>4</sup>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; <sup>5</sup>Centre for Tumour Biology, John Vane Science Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK; <sup>6</sup>Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; <sup>7</sup>Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK

Correspondence should be addressed to J.M. ([john.maher@kcl.ac.uk](mailto:john.maher@kcl.ac.uk))

Division of Cancer Studies, Guy's Hospital, Third floor Bermondsey Wing, Great Maze Pond, London SE1 9RT, United Kingdom; Telephone +44 (0)207 188 1468; Fax +44 (0)207 188 0919

Work undertaken in London, United Kingdom

Short title: CAR targeted against  $\alpha\text{v}\beta 6$  integrin in solid tumors

## INTRODUCTION

Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered autologous T-cells has achieved unprecedented efficacy in the treatment of patients with refractory B-cell malignancy.<sup>1-3</sup> In this context, the CD19 molecule provides a target par excellence, since toxicity arising from the depletion of healthy B-cells can be mitigated with immunoglobulin replacement therapy. However, solid tumors present several additional hurdles to the development of effective CAR T-cell immunotherapy. Unlike B-cell malignancy, lineage-restricted molecules are generally unsuitable for targeting owing to their expression at high levels by one or more critical organs. Broadly speaking, two alternative approaches warrant consideration. First, tumor-specific mutations (eg epidermal growth factor receptor variant III) provide attractive opportunities for immunotherapy of selected cancers.<sup>4,5</sup> However, target expression is sporadic, subject to intra-tumoral heterogeneity and downregulation upon disease relapse.<sup>6,7</sup> Alternatively, targeting may be directed against molecules that are over-expressed on transformed cells relative to healthy tissue, such as ErbB2. While initial clinical testing resulted in lethal toxicity,<sup>8</sup> more recent evaluation of this strategy has demonstrated that an efficacy signal can be achieved safely using CAR<sup>+</sup> T-cells.<sup>9</sup> This provides a strong rationale for the identification and validation of additional targets that are not absolutely tumor specific, but which are strongly upregulated on transformed cells and contribute to disease pathogenesis.

One such candidate is the epithelial-specific integrin,  $\alpha v\beta 6$ . Cell surface expression requires pairing of the monogamous  $\beta 6$  chain with the more promiscuous  $\alpha v$  partner.<sup>10</sup>  $\alpha v\beta 6$  is commonly over-expressed in solid tumors derived from pancreas, head and neck, skin, lung, esophagus,

stomach, colon, breast, uterine cervix and fallopian tube/ovary and is generally associated with worsened prognosis.<sup>11-17</sup> In keeping with this,  $\alpha\text{v}\beta 6$  activates pro-transforming growth factor- $\beta$  and promotes epithelial to mesenchymal transition, cellular migration and matrix metalloproteinase activity.<sup>18-21</sup> By contrast, this integrin is minimally expressed in adult tissue, except during wound healing.<sup>17,22</sup> In light of these attributes,  $\alpha\text{v}\beta 6$  has attracted significant interest as a target for antibody-based imaging and treatment of many cancer types.<sup>14,23,24</sup>

Infection of several species by the foot and mouth disease virus (FMDV) is mediated by the ability of the viral protein 1 coat protein to bind to a number of integrins, including  $\alpha\text{v}\beta 6$ .<sup>25</sup> A derived 20mer peptide (A20FMDV2) has been characterized as an effective antagonist of  $\alpha\text{v}\beta 6$ <sup>26</sup> and has been used to image  $\alpha\text{v}\beta 6$ -positive tumors.<sup>27</sup> We hypothesized that this 20mer would represent a suitable moiety to engineer an  $\alpha\text{v}\beta 6$ -targeted CAR since it contains two overlapping  $\alpha\text{v}\beta 6$ -binding motifs (RGD and DLXXL) and binds with >1000-fold greater specificity to this integrin than to other family members, such as  $\alpha\text{v}\beta 3$ ,  $\alpha\text{v}\beta 5$  and  $\alpha 5\beta 1$ .<sup>13,28</sup> Using A20FMDV2 as a targeting moiety, we describe for the first time the development of an  $\alpha\text{v}\beta 6$ -specific CAR that elicits potent therapeutic activity against diverse solid tumor types, without significant toxicity.

## RESULTS

### **$\alpha$ v $\beta$ 6 integrin is expressed by cell lines derived from multiple solid tumors**

**Supplementary Figure S1** shows  $\alpha$ v $\beta$ 6 expression by the panel of human tumor cells used in this study. High-level expression (100% positive; geometric mean fluorescence intensity (MFI)>2000) was found in pancreatic ductal adenocarcinoma (PDAC) cell lines (Panc0403, BxPC3), in BT20 triple negative breast cancer (TNBC) cells and in the clear cell epithelial ovarian carcinoma (EOC) cell line, OVSAYO. Intermediate expression (MFI 1000–2000) was observed in the PDAC cell line, CFPAC1, the TNBC cell line MDA-MB-468 and in the SKOV-3, OVMANA, TUOC1 and OVTOKO EOC cell lines. Lower expression (MFI 150-999) was detected in luminal (T47D, MCF7, ZR75) and luminal/ HER2<sup>+</sup> (BT474) breast cancer cells and in the OVSAHO, HAC2, SMOV2, OVAS and KK EOC cell lines. Minimal expression (MFI<150;  $\leq$ 9%<sup>+</sup> events) was found in the PDAC cell line Panc-1, the TNBC cell line CAL51, and in the A2780, A2780CP, Kuramochi and TOV21G EOC cell lines.

### **Comparison of *in vitro* anti-tumor activity of candidate $\alpha$ v $\beta$ 6-targeted CARs**

To engineer candidate  $\alpha$ v $\beta$ 6 CARs, the A20FMDV2 peptide (A20)<sup>26</sup> or a phage display-derived 12mer peptide (B12)<sup>29</sup> were fused to a human CD28 spacer (from amino acid 114, in which MYPPPY was replaced by a 9e10 myc tag), followed by a CD28+ transmembrane/endodomain and CD3 $\zeta$  endodomain. CARs were named A20-28z and B12-28z and contain two or one  $\alpha$ v $\beta$ 6 binding sites respectively (**Figure 1a-b**). A scrambled derivative of A20 (C20, in which RGDL is replaced by AAAA; **Figure 1a**) or truncated CD28 endodomain (**Figure 1c**) were used to

create control CARs (named C20-28z and A20-Tr respectively)<sup>30</sup> (**Figure 1b-c**). CARs were stoichiometrically co-expressed using a *Thyosa Asigna* (T)2A peptide-containing vector with a chimeric cytokine receptor 4 $\alpha\beta$  (**Figure 1d**) to enable preferential expansion of  $\alpha\beta6$ -re-targeted T-cells *ex vivo*. All CARs were delivered to human T-cells using the SFG retroviral vector (**Figure 1e**).

To compare function, human CAR T-cells were co-cultivated with PDAC tumor cells that naturally express minimal (min; Panc-1), intermediate (CFPAC1) or high levels of  $\alpha\beta6$  (Panc0403, BxPC3). A20-28z<sup>+</sup> T-cells released large quantities of interferon (IFN)- $\gamma$  when co-cultivated with  $\alpha\beta6$ <sup>+</sup> PDAC cells, accompanied by tumor cell killing, monolayer destruction and enrichment of transduced T-cells following CAR stimulation (**Supplementary Figure S2**). By contrast, cytotoxic activity of B12-28z<sup>+</sup> T-cells, was minimal or absent and was unaccompanied by reproducible cytokine release or CAR T-cell enrichment following stimulation (**Supplementary Figure S2** and data not shown).

In light of these findings, A20-28z was advanced and B12-28z was discarded. Specificity of integrin targeting was evaluated in cytotoxicity assays using A375 cells that naturally express several RGD-binding integrins, including  $\alpha\beta3$ ,  $\alpha\beta5$ ,  $\alpha\beta8$  and  $\alpha5\beta1$  but not  $\alpha\beta6$  (**Figures 1f and 1g**).<sup>24</sup> Comparison was made with cytotoxicity against a  $\beta6$ <sup>+</sup> A375 derivative (**Figure 1g**). In an extended cytotoxicity assay that lasted 1 – 7 days, A20-28z<sup>+</sup> T-cells killed  $\beta6$ <sup>+</sup> but not control A375 cells (**Figure 1h**), accompanied by  $\beta6$ -dependent IFN- $\gamma$  release (**Figure 1i**). As expected, neither A20-Tr<sup>+</sup> nor C20-28z<sup>+</sup> T-cells demonstrated cytotoxic activity in these assays. In order to further characterise the specificity of the A20 peptide, its binding capacity for other integrins was

also assessed. Addition of increasing amounts of biotinylated A20 peptide led to proportionately greater binding to both A375  $\beta$ 6 cells (**Figure 1j**) and to recombinant  $\alpha\beta$ 6 (**Figure 1k**). By contrast, the A20 peptide did not exhibit any detectable binding to A375 puro cells or to other RGD-binding integrins (**Figure 1j-k**).

### **Expansion of $\alpha\beta$ 6 re-targeted T-cells using interleukin-4**

To preferentially expand  $\alpha\beta$ 6-re-targeted T-cells *ex vivo*, CARs were stoichiometrically co-expressed using a *Thosea Asigna* (T)2A peptide-containing vector with  $4\alpha\beta$  (**Figure 1e**). The  $4\alpha\beta$  chimeric cytokine receptor comprises the human IL-4 receptor- $\alpha$  ectodomain which has been fused to the shared human IL-2/ IL-15 receptor  $\beta$  transmembrane and endodomain regions. Binding of the poorly mitogenic cytokine IL-4 leads to the delivery of a potent and selective growth signal in  $4\alpha\beta^+$  T-cells.<sup>31</sup> Consequently, all  $4\alpha\beta^+$  CAR T-cell populations underwent selective enrichment and expansion when cultured in IL-4 (**Supplementary Figure S3a**). Addition of exogenous IL-4 significantly increased cytotoxicity of A20-28z/ $4\alpha\beta$  T-cells against BxPC3 cells *in vitro* (**Supplementary Figure S3b**), accompanied by a non-significant trend towards increased IFN- $\gamma$  release (**Supplementary Figure S3c**). Neither the co-expression of  $4\alpha\beta$  nor the addition of IL-4 resulted in an alteration in the proportion of CAR T-cells with naïve ( $CCR7^+CD45RO^-$ ), central memory ( $CCR7^+CD45RO^-$ ), effector memory ( $CCR7^-CD45RO^+$ ) or effector ( $CCR7^-CD45RO^-$ ) phenotype, when compared to cells cultured in IL-2 (**Supplementary Figure S3d**).

### **$\alpha\beta6$ -retargeted CAR T-cells elicit broad anti-tumor activity *in vitro***

Following IL-4-mediated expansion *in vitro*, A20-28z/4 $\alpha\beta^+$  and control C20-28z/4 $\alpha\beta^+$  or A20-Tr/4 $\alpha\beta^+$  T-cells were evaluated for anti-tumor activity using a panel of cell lines that express varying levels of  $\alpha\beta6$ . Unlike controls, A20-28z $^+$  T-cells killed  $\alpha\beta6^+$  PDAC, HER2 amplified breast, luminal breast, TNBC and ovarian tumor cells (**Figure 2a-e**), accompanied by release of IL-2 (**Figure 3**) and IFN- $\gamma$  (**Supplementary Figure S4**). Residual tumor cell viability and cytokine release correlated inversely or directly (respectively) with intensity of  $\alpha\beta6$  expression on target cells (**Figure 4**). Importantly however, tumor cells that expressed very low levels of  $\alpha\beta6$  (eg Panc-1; **Figure 2a** or CAL51; **Figure 2d**) were not killed.

### **$\alpha\beta6$ re-targeted CAR T-cells cause regression of several tumor xenografts with minimal toxicity**

Firefly luciferase (fluc) $^+$  SKOV-3 cells express  $\alpha\beta6$  and can be propagated as an intraperitoneal (i.p.) xenograft that is amenable to monitoring using bioluminescence imaging (BLI).<sup>32</sup> Consequently, this provides a convenient model to test *in vivo* anti-tumor activity of adoptively transferred  $\alpha\beta6$  re-targeted CAR T-cells. To permit T-cell imaging, co-transduction was performed with A20-28z/4 $\alpha\beta$  (or the control A20-Tr/4 $\alpha\beta$  retroviral vector) and a second retroviral vector that encodes for green fluorescent protein (GFP) and red-shifted *Renilla* luciferase (rluc; **Figure 1l**). After IL-4-mediated *ex vivo* enrichment for CAR T-cell expression, transduced T-cells were analysed for expression of CD8 and retroviral-encoded transgenes (**Figure 5a**). Functionality of CAR T-cells was confirmed *in vitro* using cytotoxicity and



cytokine release assays (data not shown) prior to i.p. transfer into SCID Beige mice with established SKOV-3 fluc xenografts.

Mice treated with control A20-Tr/4 $\alpha\beta$ /rluc/GFP<sup>+</sup> CAR T-cells or PBS had progressive disease. By contrast, mice treated with A20-28z/4 $\alpha\beta$ /rluc/GFP<sup>+</sup> CAR T-cells exhibited tumor regression within 5 days of treatment and maintained a significantly lower tumor burden than either control group (**Figure 5b-c**). Treatment with  $\alpha\beta$ 6-retargeted CAR T-cells significantly extended median survival from 63 days (both control groups) to 82 days (A20-28z group;  $p = 0.0014$ ) (**Supplementary Figure S5**). Although the A20-28z CAR can also recognize  $\alpha\beta$ 6 expressed by murine cells, treatment was very well tolerated. Minimal weight loss (<5%) was observed in some mice, with complete resolution within 1 week (**Figure 5d**). This contrasts with severe weight loss and cytokine release syndrome (CRS) that may be induced in the same tumor xenograft model using ErbB retargeted CAR T-cells.<sup>33</sup>

To investigate the generality of these findings, similar experiments were performed in which BxPC3 (**Figure 6**), MDA-MB-468 (**Figure 7**) or Panc0403 (**Figure 8**) tumor xenografts were established in SCID Beige mice. As before, T-cells were dual transduced to co-express rluc/GFP with A20-28z/4 $\alpha\beta$  or A20-Tr/4 $\alpha\beta$  and enriched for CAR<sup>+</sup> T-cells by *ex vivo* culture in IL-4. Prior to adoptive transfer, T-cells were analysed for transgene expression (**Figure 6a, 7a, 8a**) and for *in vitro* cytotoxicity and cytokine release following co-culture with  $\alpha\beta$ 6<sup>+</sup> tumor cells (data not shown). In all cases, mice treated with either PBS or A20-Tr/4 $\alpha\beta$ /rluc/GFP<sup>+</sup> T-cells demonstrated similar levels of tumor progression whereas A20-28z/4 $\alpha\beta$ /rluc/GFP<sup>+</sup> CAR T-cells caused significant tumor regression (BxPC3 – **Figure 6b-c**; MDA-MB-468 – **Figure 7b-c**) or

stabilization (Panc0403 - **Figure 8b**) followed by delayed disease progression. Tumor regression was observed in the Panc0403 model in a second experiment, following treatment with A20-28z<sup>+</sup> T-cells (**Supplementary Figure S6**). Anti-tumor activity of  $\alpha\nu\beta 6$ -retargeted CAR T-cells was associated with transient minor and fully reversible weight loss (**Figure 6d, 7d, 8c**).

### **T-cell imaging demonstrates inadequate longevity of human CAR T-cells in SCID Beige mice**

Engineering of CAR T-cells to co-express rluc/GFP allowed serial monitoring of the bio-distribution of CAR T-cells using BLI. It also provides quantitative information since we found that the number of CAR T-cells present correlated directly with total flux (**Supplementary Figure S7**). *Renilla* luciferase utilizes a different substrate (coelenterazine) than fluc (d-luciferin), which is expressed by tumor cells in these models, allowing separate imaging of T-cells and tumor in the same animals. Using this approach, we found that incomplete eradication of tumor burden correlated with progressive loss of CAR T-cells following adoptive transfer, although a small residual population of CAR T-cells was frequently detected (Panc0403 model; **Figure 8d**). Similar results were obtained in the SKOV-3 and BxPC3 models (data not shown). Administration of exogenous IL-4 exerted only a marginal impact on therapeutic activity when limiting numbers of CAR T-cells were used to treat mice with advanced tumor burden (**Supplementary Figure S8a**). This was accompanied by a non-significant trend towards delayed loss of CAR T-cells in mice treated with high-dose IL-4 (**Supplementary Figure S8b**). Combination treatment with CAR T-cells and IL-4 was not toxic, indicated by lack of weight loss in treated mice (**Supplementary Figure S8c**).

## **Human CAR T-cells recognize mouse $\alpha\text{v}\beta 6$ but cause mild, transient and fully reversible toxicity at supra-therapeutic dose levels**

The FMDV 20mer also binds mouse  $\alpha\text{v}\beta 6$  with high affinity.<sup>28</sup> To test if human A20-28z<sup>+</sup> T-cells engage the mouse  $\alpha\text{v}\beta 6$  ortholog, co-cultivation experiments were performed using 4T1 mammary tumor cells, which naturally express this integrin (data not shown). Unlike control T-cells, human A20-28z<sup>+</sup> T-cells destroyed 4T1 tumor cells, accompanied by release of IFN- $\gamma$  (**Supplementary Figure S9** and data not shown).

We have previously shown that CAR T-cells delivered using the i.p. route remain largely in the peritoneal cavity.<sup>34</sup> Nonetheless, they can trigger severe macrophage-dependent cytokine release syndrome (CRS), particularly in the presence of advanced tumor burden.<sup>33</sup> Such toxicity was not seen in the tumor xenograft models presented above. However, i.p. delivery may not permit human CAR T-cells to access all sites where  $\alpha\text{v}\beta 6$  is naturally expressed in mice, notably gastrointestinal epithelium.<sup>28</sup> Consequently, we performed a study in which bolus doses of CAR T-cells were administered i.v. to these animals. A single dose of  $20 \times 10^6$  CAR T-cells resulted in no weight loss or other clinical manifestations of toxicity. By contrast, when  $40 \times 10^6$  A20-28z/4 $\alpha\beta^+$  T-cells were administered in two divided doses over 24 hours, significant weight loss was observed which was transient and fully reversible. Toxicity was dependent on an intact CAR since it was not observed with T-cells that expressed the truncated A20-Tr control (**Supplementary Figure S10**).

## DISCUSSION

Aberrant expression of the epithelial-specific integrin  $\alpha\text{v}\beta 6$  is prevalent in several cancers.<sup>11-16,18</sup> The pro-invasive effect of  $\alpha\text{v}\beta 6$  is most graphically illustrated by its predominant expression at the infiltrating margin of the tumor mass.<sup>11</sup> By contrast, expression of this integrin is scarcely detectable in healthy human tissues,<sup>17,22</sup> rendering it a highly attractive candidate for immunotherapeutic targeting. Here, we show for the first time that T cells engineered to express an  $\alpha\text{v}\beta 6$ -specific CAR mediate therapeutic activity against a broad range of solid tumor types, both *in vitro* and *in vivo*.

To engineer candidate  $\alpha\text{v}\beta 6$ -targeted CAR T-cells, two integrin-binding peptides were coupled to matched hinge, transmembrane and CD28+CD3 $\zeta$  endodomain modules. The FMDV-derived A20 peptide has been extensively characterised for its ability to bind specifically to  $\alpha\text{v}\beta 6$  but not to other  $\alpha\text{v}$ -based heterodimeric integrins. We found that T-cells engineered to express an A20-derived CAR (A20-28z) killed tumor cell types of diverse origin, accompanied by cytokine release. Importantly, the magnitude of these effector activities correlated closely with cell surface expression of  $\alpha\text{v}\beta 6$  integrin, meaning that target cells with very low levels of  $\alpha\text{v}\beta 6$  (e.g. Panc-1, CAL51) were ignored. We also evaluated an alternative second generation CAR that was targeted using a 12mer peptide, isolated by phage display.<sup>29</sup> The B12 peptide had been used to engineer a first-generation CAR to which some *in vitro* anti-tumor activity had been attributed.<sup>35</sup> However, this was demonstrated using a re-stimulated CD8<sup>+</sup> T-cell line (isolated following hygromycin selection) and two derived CD8<sup>+</sup> T-cell clones. When we re-evaluated this peptide in the context of a second generation CAR which was expressed in unselected primary human T-

cells, negligible anti-tumor activity was observed. Given that the B12 peptide is shorter, it is possible that cognate epitope is not accessible by this very short peptide. Consequently, A20-28z alone was advanced for further study.

*In vivo* efficacy of A20-28z CAR T-cells was demonstrated in four established xenograft models, representative of PDAC, breast and ovarian cancer. Using a dual BLI imaging strategy, we demonstrated that  $\alpha\nu\beta 6$  re-targeted A20-28z<sup>+</sup> CAR T-cells declined progressively in the days following delivery. This may account for the delayed tumor relapse observed, providing a rationale for the exploration of repeated T-cell administration in future studies.<sup>32</sup>

Prior to adoptive transfer, genetically engineered T-cells were enriched during *ex vivo* expansion since the CAR was co-expressed with 4 $\alpha\beta$ , a chimeric cytokine receptor that allows selective IL-4-mediated proliferation of CAR T-cells.<sup>31</sup> This approach is now in use in a Phase 1 clinical trial in patients with locally advanced or recurrent head and neck cancer. In that setting, a broadly reactive ErbB-specific CAR is co-expressed with 4 $\alpha\beta$ , allowing IL-4-mediated expansion of cell products prior to intra-tumoral delivery.<sup>37</sup> This approach obviates the need for leukapheresis since over 2 billion CAR<sup>+</sup> T-cells can reliably be expanded/ enriched within 2 weeks from 120mL blood, even from patients with advanced malignancy and profound lymphopenia. To date, eight CAR T-cell batches have been produced in this ongoing trial that have exceeded these specifications, without any batch failures (data not shown).

In our study, we used the 4 $\alpha\beta$  system as a means of *in vitro* expansion. However, IL-4 is also produced *in vivo* in humans, and may be overproduced in the tumor microenvironment. As

discussed previously,<sup>31</sup> this could theoretically benefit anti-tumor activity but might also enhance toxicity of this approach. In our study, we found that provision of exogenous IL-4 cytokine support did not improve anti-tumor activity of CAR T-cells or their long-term survival. This may have been because of the very short half-life of IL-4 *in vivo*. Moreover, combination IL-4 and CAR T-cell treatment did not increase toxicity, although human IL-4 is not active in the mouse.

Meaningful safety testing of human A20-28z<sup>+</sup> CAR T-cells could be undertaken in SCID Beige mice for three reasons. First, the A20 FMDV targeting moiety can bind to mouse  $\alpha\text{v}\beta 6$  integrin with comparable affinity to the human ortholog.<sup>28</sup> As a result, human A20-28z<sup>+</sup> CAR T-cells also recognize mouse tumor cells that express this integrin. Second, we have previously shown that i.p. delivery of human ErbB re-targeted CAR T-cells can elicit severe CRS in SCID Beige mice, in a manner that is accentuated by high tumor burden. In that setting, macrophage activation (a functionality that is preserved in SCID Beige mice) accompanied by IL-6 release play a pivotal role,<sup>33</sup> recapitulating the key role of these intermediates in human CRS.<sup>38</sup> Third, expression of  $\alpha\text{v}\beta 6$  in mice is proportionately greater than in man, most notably in the gastrointestinal tract.<sup>28</sup> In keeping with this, laboratory mice are highly susceptible to FMDV,<sup>39</sup> unlike man in which this viral illness is an extraordinarily unusual zoonosis.<sup>40</sup> Reassuringly however, minimal toxicity accompanied tumor regression in all four xenograft models following treatment with  $\alpha\text{v}\beta 6$ -targeted A20-28z CAR T-cells. Administration of very large doses using the i.v. route did result in reversible toxicity which was dependent upon an intact  $\alpha\text{v}\beta 6$ -targeted CAR.

Taken together, these data justify the evaluation of  $\alpha\text{v}\beta 6$ -targeted CAR T-cell immunotherapy for tumors in which aberrant expression of this integrin is present. We are currently developing a

strategy for Phase 1 evaluation of this approach in patients with otherwise untreatable  $\alpha v\beta 6$ -expressing malignancy.

## MATERIALS AND METHODS

**Retroviral constructs.** To enable detection of CARs, a myc epitope-tagged framework was engineered (**Figure 1b-d**). A codon-optimized cDNA was synthesized to encode for human CD28 (amino acids 114 to 200) in which B7-binding residues 117-122 (MYPPPY) were substituted with residues 410-419 of human c-myc (EQKLISEEDL) (Mr Gene, Regensburg, Germany). The sequence was flanked by 5' Not1 and 3' Apa1 restriction sites and was substituted for the corresponding fragment in SFG T1E28z, (encodes a broadly ErbB reactive CAR with a CD28+CD3 $\zeta$  endodomain).<sup>41</sup> The resultant myc epitope-tagged CAR (Tm28z) exhibited comparable function to T1E28z (data not shown). Next, codon-optimized cDNAs were synthesized in which two candidate  $\alpha\beta 6$ -binding peptide sequences were fused to signal peptides selected for correct cleavage site using SignalP 3.0 server [42] (Genscript, Piscataway, NJ; **Figure 1a**). The VP1-derived A20FMDV2 20mer peptide was placed downstream of a CD124 signal peptide (A20).<sup>43</sup> A control ( $\alpha\beta 6$  non-binding) peptide was generated in which the RGDL motif within A20FMDV2 was substituted with AAAA (C20). To engineer an alternative CAR targeting moiety, a previously described  $\alpha\beta 6$ -binding 12mer peptide (isolated by phage display).<sup>29,35</sup> was placed downstream of a human CD3 $\gamma$  signal peptide (B12) (**Figure 1a**). All cDNAs were substituted for the smaller Nco1/Not1 fragment within SFG Tm28z. The resultant CARs were named A20-28z, C20-28z and B12-28z (**Figure 1b**). An endodomain truncated control CAR (A20-Tr) was also engineered in which the Not1/ Xho1 fragment within A20-28z was substituted with a smaller synthetic cDNA (Genscript) encoding CD28 residues 114-182 (in which MYPPPY was replaced by the myc epitope tag; **Figure 1c**).



In most experiments, CARs were co-expressed with an IL-4-responsive chimeric cytokine receptor (4αβ, in which the IL-4 receptor-α ectodomain is fused to the shared transmembrane/endodomain of IL-2/15 receptor-β; **Figure 1d**). T-cells that express 4αβ undergo selective enrichment and expansion when cultured in IL-4.<sup>31</sup> Stoichiometric co-expression was achieved using an intervening furin cleavage site (RRKR), [serine-glycine]<sub>2</sub> linker and *Thomomys Asigna* 2A (T2A) peptide (**Figure 1e**).<sup>31</sup>

To visualize T-cells *in vivo*, a red-shifted *Renilla reniformis* luciferase 8.6-535 (rluc; Genscript)<sup>44</sup> was co-expressed with GFP in a single SFG retroviral vector containing a furin cleavage site and T2A peptide (SFG rluc/GFP; **Figure 1l**). To visualize tumors *in vivo*, firefly luciferase (ffluc) was co-expressed with tdTomato red fluorescent protein (tdRFP; Genscript) in a single SFG retroviral vector containing a furin cleavage site and T2A peptide (SFG ffluc/tdTom; **Figure 1m**).

**Culture and retroviral transduction of primary human T-cells.** Blood samples were obtained from healthy volunteers with approval of the South East London Research Ethics Committee 1 (reference 09/H0804/92). Activation of T-cells was achieved 48h prior to gene transfer using CD3+CD28-coated paramagnetic beads (1:1 bead: cell ratio; Thermo Fisher Scientific, Paisley UK). Gene transfer was performed using PG13 retroviral packaging cells as described.<sup>45</sup> Transduced T-cells were cultured in RPMI-1640 supplemented with 10% human AB serum (Sigma, Poole, UK), GlutaMax and antibiotic-antimycotic solution (Thermo Fisher Scientific) and in the presence of either 100U/ml IL-2 (Proleukin, Novartis, Frimley, UK), or 30ng/ml IL-4 (Gentaur, Kampenhout, Belgium).

**Cell lines.** Ffluc<sup>+</sup> Panc-1, BxPC3, ffluc<sup>+</sup> CFPAC1, ffluc<sup>+</sup> Panc0403, A375 puro (transduced with pBabe puro retrovirus), A375- $\beta$ 6 (transduced with pBabe puro retrovirus that encodes for human  $\beta$ 6), A2780, A2780CP and TOV21G cells were obtained from the Barts Cancer Institute, Queen Mary University of London. Ffluc<sup>+</sup> SKOV-3 cells were purchased from Caliper (PerkinElmer, Waltham MA). Kuramochi and OVSAHO cells were obtained from the Japanese Collection of Research Bio-resources Cell Bank. The clear cell lines OVAS, SMOV2, KK, HAC2, OVTOKO, OVSAYO, TUOC1 and OVMANA were a kind gift from Dr Itamochi, Tottori University School of Medicine, Japan. The breast cancer cell lines CAL51, BT20, MDA-MB-468, MCF7, BT474 and ZR75-1 were obtained from the Breast Cancer Now Research Unit, King's College London. Tumor cell lines were grown in R10 or D10 medium, respectively comprising RPMI or DMEM (Lonza, Basel, Switzerland) supplemented with 10% FBS (Sigma), GlutaMax and antibiotic-antimycotic solution (Life Technologies). PG13 retroviral packaging cells were obtained from the European Collection of Cell Cultures (ECACC, Porton Down, UK) and were maintained in D10. H29 retroviral packaging cells were a gift from Dr. Michel Sadelain (Memorial Sloan Kettering Cancer Center, NY) and were propagated as described.<sup>45</sup> All tumor cell lines were validated by short tandem repeat DNA profiling and experiments were performed within 30 passages of receipt.

**Flow cytometry analysis.** Expression of  $\alpha$ v $\beta$ 6 was detected using the 6.3G9 antibody,<sup>46</sup> followed by goat anti-mouse Ig-PE (Dako, Ely, UK) and was expressed as percentage positivity and/ or geometric mean fluorescence intensity. Cells stained with secondary antibody only served as a negative control. Expression of CARs was detected using supernatant derived from

the 9e10 hybridoma (ECACC), which binds to residues 410-419 of human c-myc, followed by goat anti-mouse Ig-PE. Untransduced T-cells acted as a negative control. CD8 expression was detected using PE-conjugated PNIM0452 (Immunotech, Marseille, France). Phenotypic analysis of T-cells was performed using anti-CCR7 (R&D systems FAB197F) and CD45RO (Biolegend 304210) antibodies. In some assays, populations were gated on CAR<sup>+</sup> cells detected using an antibody against CD124 (BD Pharmingen, 552178). To assess integrin specificity of the A20 peptide, biotinylated peptide (Genscript, Hong Kong Ltd) was diluted in PBS supplemented with MgCl<sub>2</sub> and NaCl (Sigma D8662) and incubated with cells on ice for 20 minutes before being stained with streptavidin-PE (LifeTech S866) for a further 20 minutes on ice. Flow cytometry was performed using a FACSCalibur cytometer with CellQuest Pro software or Fortessa cytometer with FACSDiva software.

**ELISA.** Supernatants from tumor/T-cell co-cultures were analyzed using a human IFN- $\gamma$  or human IL2 ELISA Ready-set-go kit (eBiosciences, Hatfield, UK), as described by the manufacturers. To assess integrin specificity of the A20 peptide, ELISA plates were coated with recombinant  $\alpha\text{v}\beta 6$  (3817-AV-050),  $\alpha\text{v}\beta 3$  (3050-AV-050),  $\alpha\text{v}\beta 5$  (2528-AV-050),  $\alpha\text{v}\beta 8$  (4135-AV-050) integrin proteins (all R&D systems) in PBS overnight. Wells were washed with PBS supplemented with MgCl<sub>2</sub> and NaCl (wash buffer) before blocking for 2 hours with 1% w/v milk in wash buffer. After washing, 100 $\mu$ l biotinylated peptide was added in 0.1% w/v milk in wash buffer for 1 hour followed by washing, and incubation with 100 $\mu$ l 1:500 dilution streptavidin-HRP (Dako P039701-2) for 1 hour. Plates were then washed and incubated with 100 $\mu$ l hydrogen peroxide/tetramethylbenzidine (R&D Substrate Reagent DY999) for 20 minutes before addition of 50 $\mu$ l of 2N sulphuric acid.

**Cytotoxicity assays.** Tumor cell monolayers (96 well plate) were incubated with T-cells for 24-72h at a 1:1 tumor cell: T-cell ratio, unless otherwise indicated. Destruction of tumor cell monolayers by T-cells was quantified using an MTT or luciferase assay. In the former, T-cells were removed and MTT (Sigma) was added at 500µg/ml in fresh D10 medium for 1-2 hours at 37°C and 5% CO<sub>2</sub>. After removal of the supernatant, formazan crystals were re-suspended in 50µL DMSO. Absorbance was measured at 560nm. In luciferase assays, D-luciferin (PerkinElmer) was added at 150µg/ml immediately prior to luminescence reading. Tumor cell viability was calculated as (absorbance or luminescence of monolayer cultured with T-cells / absorbance or luminescence of untreated monolayer alone) x 100 %.

***In vivo* studies.** All *in vivo* experimentation adhered to U.K. Home Office guidelines, as specified in project license number 70/7794 and was approved by the King's College London animal welfare committee. Where necessary, tumor cells were transduced with SFG ffluc/tdTom and were purified by flow sorting prior to engraftment *in vivo*. SKOV-3 ( $1 \times 10^6$  cells), MDA-MB-468, Panc0403 or BxPC3 ( $2 \times 10^6$  cells each) were inoculated i.p. into SCID Beige mice. Engineered T-cells ( $1-2 \times 10^7$  cells in total as indicated in individual experiments) were administered i.p. on day 14 (BxPC3, Panc0403), day 21 (SKOV-3) or day 42 (MDA-MB-468). Bioluminescence imaging was performed using an IVIS Spectrum Imaging platform (PerkinElmer) with Living Image software (PerkinElmer). To image tumor status, mice were injected i.p. with D-luciferin (150 mg/kg; PerkinElmer) and imaged under isoflurane anesthesia after 12 min. To image T-cells, mice were injected i.p. with coelenterazine (30µg/mouse; PerkinElmer) and imaged under isoflurane anesthesia after 30 min. Image acquisition was

conducted on a 15- or 25-cm field of view with medium binning and auto-exposure. To assess safety of CAR T-cells, i.v. bolus doses of 20 million CAR T-cells were administered at the indicated intervals, making comparison with PBS. To assess the effect of exogenous  $1 \times 10^5$  BxPC3 cells were inoculated i.p into NSG mice before treatment with  $2.5 \times 10^6$  T-cells i.p +/- hIL-4 (Miltenyi). Interleukin-4 was administered three times weekly i.p thereafter. In all experiments, animals were inspected daily and weighed weekly. Mice were culled if symptomatic as a result of tumor progression or weight loss of  $\geq 20\%$ .

**Statistical analysis.** For comparison of two groups, datasets were analyzed using two-tailed Student's *t* test. Survival data were analysed using the Log-rank (Mantel-Cox) test. Correlation between intensity of  $\alpha\beta 6$  expression and T-cell effector function was determined using Pearson *r* correlation. All statistical analysis was performed using GraphPad Prism version 5.0 or 6.0 (GraphPad software, San Diego, CA) or Excel for Mac 2011 (Berkshire, UK).

## **AUTHOR CONTRIBUTIONS**

Conception and design: JM, JFM, LMW. Laboratory work: LMW, ACPP, TZ, DMD, RMGP, YVK, SAS, AR, JACG, SVallath. Provision of essential materials and advice: SViolette, HI, SGM, JFM. Drafting of manuscript: LMW, JM. Critically revising manuscript: all authors.

## **ACKNOWLEDGEMENTS**

This research was supported by Worldwide Cancer Research (13-1017), Breast Cancer Now (2010MayPR33), Pancreatic Cancer UK (A16648), the Experimental Cancer Medicine Centre at King's College London and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors have no conflicting interests. We thank Anthony Walker and Mike Garrison for useful discussions.

## **DISCLOSURE/CONFLICT OF INTEREST**

JM is chief scientific officer of Leucid Bio, which is a spinout company focused on development of cellular therapeutic agents. There are no other conflicts of interest to disclose.

## REFERENCES

1. Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, *et al.* (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* **6**: 224ra225.
2. Maude, S, Frey, N, Shaw, P, Aplenc, R, Barrett, D, Bunin, N, *et al.* (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* **371**: 1507-1517.
3. Kochenderfer, JN, Dudley, ME, Kassim, SH, Somerville, RP, Carpenter, RO, Stetler-Stevenson, M, *et al.* (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol* **33**: 540-549.
4. Morgan, RA, Johnson, LA, Davis, JL, Zheng, Z, Woolard, KD, Reap, EA, *et al.* (2012). Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. *Hum Gene Ther* **23**: 1043-1053.
5. Johnson, LA, Scholler, J, Ohkuri, T, Kosaka, A, Patel, PR, McGettigan, SE, *et al.* (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Sci Transl Med* **7**: 275ra222.
6. Del Vecchio, CA, Giacomini, CP, Vogel, H, Jensen, KC, Florio, T, Merlo, A, *et al.* (2013). EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. *Oncogene* **32**: 2670-2681.
7. Montano, N, Cenci, T, Martini, M, D'Alessandris, QG, Pelacchi, F, Ricci-Vitiani, L, *et al.* (2011). Expression of EGFRvIII in glioblastoma: prognostic significance revisited. *Neoplasia* **13**: 1113-1121.
8. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM, and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther* **18**: 843-851.
9. Ahmed, N, Brawley, VS, Hegde, M, Robertson, C, Ghazi, A, Gerken, C, *et al.* (2015). Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. *J Clin Oncol*. **33**: 1688-1696.
10. Hynes, RO (2002). Integrins: bidirectional, allosteric signaling machines. *Cell* **110**: 673-687.
11. Van Aarsen, LA, Leone, DR, Ho, S, Dolinski, BM, McCoon, PE, LePage, DJ, *et al.* (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. *Cancer Res* **68**: 561-570.
12. Hazelbag, S, Kenter, GG, Gorter, A, Dreef, EJ, Koopman, LA, Violette, SM, *et al.* (2007). Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. *J Pathol* **212**: 316-324.
13. Elayadi, AN, Samli, KN, Prudkin, L, Liu, YH, Bian, A, Xie, XJ, *et al.* (2007). A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. *Cancer Res* **67**: 5889-5895.



14. Moore, KM, Thomas, GJ, Duffy, SW, Warwick, J, Gabe, R, Chou, P, *et al.* (2014). Therapeutic targeting of integrin alphavbeta6 in breast cancer. *J Natl Cancer Inst* **106**: dju169.
15. Ahmed, N, Riley, C, Rice, GE, Quinn, MA, and Baker, MS (2002). Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. *J Histochem Cytochem* **50**: 1371-1380.
16. Sipos, B, Hahn, D, Carceller, A, Piulats, J, Hedderich, J, Kalthoff, H, *et al.* (2004). Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. *Histopathology* **45**: 226-236.
17. Thomas, GJ, Nystrom, ML, and Marshall, JF (2006). Alphavbeta6 integrin in wound healing and cancer of the oral cavity. *J Oral Pathol Med* **35**: 1-10.
18. Bates, RC, Bellocin, DI, Brown, C, Maynard, E, Wu, B, Kawakatsu, H, *et al.* (2005). Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. *J Clin Invest* **115**: 339-347.
19. Thomas, GJ, Lewis, MP, Whawell, SA, Russell, A, Sheppard, D, Hart, IR, *et al.* (2001). Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. *J Invest Dermatol* **117**: 67-73.
20. Thomas, GJ, Lewis, MP, Hart, IR, Marshall, JF, and Speight, PM (2001). AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. *Int J Cancer* **92**: 641-650.
21. Morgan, MR, Thomas, GJ, Russell, A, Hart, IR, and Marshall, JF (2004). The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. *J Biol Chem* **279**: 26533-26539.
22. Breuss, JM, Gallo, J, DeLisser, HM, Klimanskaya, IV, Folkesson, HG, Pittet, JF, *et al.* (1995). Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. *J Cell Sci* **108** ( Pt 6): 2241-2251.
23. Eberlein, C, Kendrew, J, McDaid, K, Alfred, A, Kang, JS, Jacobs, VN, *et al.* (2013). A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. *Oncogene* **32**: 4406-4416.
24. Kogelberg, H, Tolner, B, Thomas, GJ, Di Cara, D, Minogue, S, Ramesh, B, *et al.* (2008). Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. *J Mol Biol* **382**: 385-401.
25. Burman, A, Clark, S, Abrescia, NG, Fry, EE, Stuart, DI, and Jackson, T (2006). Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav integrins. *J Virol* **80**: 9798-9810.
26. DiCara, D, Rapisarda, C, Sutcliffe, JL, Violette, SM, Weinreb, PH, Hart, IR, *et al.* (2007). Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. *J Biol Chem* **282**: 9657-9665.
27. Hausner, SH, DiCara, D, Marik, J, Marshall, JF, and Sutcliffe, JL (2007). Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. *Cancer Res* **67**: 7833-7840.

28. Saha, A, Ellison, D, Thomas, GJ, Vallath, S, Mather, SJ, Hart, IR, *et al.* (2010). High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. *J Pathol* **222**: 52-63.
29. Kraft, S, Diefenbach, B, Mehta, R, Jonczyk, A, Luckenbach, GA, and Goodman, SL (1999). Definition of an unexpected ligand recognition motif for alphav beta6 integrin. *J Biol Chem* **274**: 1979-1985.
30. Maher, J, Brentjens, RJ, Gunset, G, Riviere, I, and Sadelain, M (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. *Nat Biotechnol* **20**: 70-75.
31. Wilkie, S, Burbidge, SE, Chiapero-Stanke, L, Pereira, AC, Cleary, S, van der Stegen, SJ, *et al.* (2010). Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. *J Biol Chem* **285**: 25538-25544.
32. Parente-Pereira, AC, Whilding, LM, Brewig, N, van der Stegen, SJ, Davies, DM, Wilkie, S, *et al.* (2013). Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin. *J Immunol* **191**: 2437-2445.
33. van der Stegen, SJ, Davies, DM, Wilkie, S, Foster, J, Sosabowski, JK, Burnet, J, *et al.* (2013). Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? *J Immunol* **191**: 4589-4598.
34. Parente-Pereira, AC, Burnet, J, Ellison, D, Foster, J, Davies, DM, van der Stegen, S, *et al.* (2011). Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. *J Clin Immunol* **31**: 710-718.
35. Pameijer, CR, Navanjo, A, Meechoovet, B, Wagner, JR, Aguilar, B, Wright, CL, *et al.* (2007). Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. *Cancer Gene Ther* **14**: 91-97.
36. Alcantar-Orozco, EM, Gornall, H, Baldan, V, Hawkins, RE, and Gilham, DE (2013). Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. *Hum Gene Ther Methods* **24**: 310-320.
37. van Schalkwyk, MC, Papa, SE, Jeannon, JP, Guerrero Urbano, T, Spicer, JF, and Maher, J (2013). Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. *Hum Gene Ther Clin Dev* **24**: 134-142.
38. Maude, SL, Barrett, D, Teachey, DT, and Grupp, SA (2014). Managing cytokine release syndrome associated with novel T cell-engaging therapies. *Cancer J* **20**: 119-122.
39. Salguero, FJ, Sanchez-Martin, MA, Diaz-San Segundo, F, de Avila, A, and Sevilla, N (2005). Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. *Virology* **332**: 384-396.
40. Prempeh, H, Smith, R, and Muller, B (2001). Foot and mouth disease: the human consequences. The health consequences are slight, the economic ones huge. *BMJ* **322**: 565-566.
41. Davies, D, Foster, J, Van Der Stegen, S, Parente-Pereira, A, Chiapero-Stanke, L, Delinassios, G, *et al.* (2012). Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. *Mol Med* **18**: 565-576.
42. Bendtsen, JD, Nielsen, H, von Heijne, G, and Brunak, S (2004). Improved prediction of signal peptides: SignalP 3.0. *J Mol Biol* **340**: 783-795.

43. Logan, D, Abu-Ghazaleh, R, Blakemore, W, Curry, S, Jackson, T, King, A, *et al.* (1993). Structure of a major immunogenic site on foot-and-mouth disease virus. *Nature* **362**: 566-568.
44. Loening, AM, Wu, AM, and Gambhir, SS (2007). Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. *Nat Methods* **4**: 641-643.
45. Parente-Pereira, AC, Wilkie, S, van der Stegen, S, Davies DM, and Maher, J (2014). Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells. *J Biol Methods* **1**: e7.
46. Weinreb, PH, Simon, KJ, Rayhorn, P, Yang, WJ, Leone, DR, Dolinski, BM, *et al.* (2004). Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. *J Biol Chem* **279**: 17875-17887.

## FIGURE LEGENDS

**Figure 1 Design and integrin specificity of retroviral-encoded CAR constructs.** (a) To create an  $\alpha\beta6$ -specific CAR targeting moiety, the A20 peptide derived from the GH-loop of the capsid protein VP1 from Foot and Mouth Disease Virus (serotype 01 BFS) was placed downstream of a CD124 signal peptide. A matched but scrambled peptide (named C20) was generated in which RGD $\Delta$ L was replaced with AAAA. A second  $\alpha\beta6$ -specific CAR targeting moiety was engineered by placing the B12 peptide downstream of a CD3 $\gamma$  signal peptide. (b) Schematic structure of  $\alpha\beta6$ -specific CARs and (c) matched endodomain-truncated control. (d) Schematic structure of 4 $\alpha\beta$  chimeric cytokine receptor in which the IL-4 receptor  $\alpha$  ectodomain is fused to the transmembrane and endodomain of the shared IL-2/15 receptor  $\beta$ . (e) The SFG retroviral vector was used to express CARs in human T-cells. LTR – long terminal repeat; S – signal peptide; T – targeting moiety; M – human c-myc epitope tag, recognized by 9e10 antibody. In some constructs, equimolar co-expression of the IL-4-responsive 4 $\alpha\beta$  chimeric cytokine receptor was achieved using a *Thosea Asigna* (T)2A ribosomal skip peptide, placed downstream of a furin cleavage site, designed to remove peptide overhangs on the C-terminus of the upstream encoded polypeptide. (f) Expression of the indicated integrins in A375 cells as detected by flow cytometry. (g) A375 cells were transduced with the pBabe puro retroviral vector (A375 puro) or with pBabe puro that encodes for the integrin  $\beta6$  subunit. Cell surface expression of  $\beta6$  was determined in both cell populations by flow cytometry. SSC – side scatter. (h) A375 puro cells ( $\alpha\beta6$ -negative) or A375  $\beta6$  cells ( $\alpha\beta6$ -positive) were co-cultivated at a 1:1 ratio with the indicated CAR engineered T-cells in the absence of exogenous cytokine. Data show the mean  $\pm$  SD of residual tumor cell viability from 5 independent experiments, each performed in triplicate.

Survival was quantified by MTT assay at 24-168h and expressed relative to untreated tumor cells (set at 100% viability). **(i)** Cells were co-cultivated at a 1:1 ratio with the indicated CAR engineered T-cells in the absence of exogenous cytokine for 48hrs. Data show the mean  $\pm$  SD of IFN- $\gamma$  detected in the cell supernatant from 3 independent experiments, each performed in duplicate. **(j)** Binding of biotinylated A20 peptide to A375 puro cells ( $\alpha\beta6$ -negative) or A375  $\beta6$  cells ( $\alpha\beta6$ -positive) was detected by flow cytometry. Data show the mean  $\pm$  SD geometric mean fluorescent intensity of 4 independent experiments. **(k)** Binding of biotinylated A20 peptide to recombinant integrins was quantified by ELISA. **(l)** SFG rluc/GFP vector, which co-expresses *Renilla* luciferase (red-shifted 8.6-535 variant) with GFP using a furin-T2A (F-T2A) intervening sequence. **(m)** SFG ffluc/tdTom vector, which co-expresses firefly luciferase with tdTomato red fluorescent protein using a F-T2A intervening sequence.

**Figure 2** *In vitro* assessment of anti-tumor activity of CAR T-cells targeted against  $\alpha\beta6$ . Firefly luciferase-expressing pancreatic **(a)**, HER2 amplified breast **(b)**, luminal breast **(c)**, triple negative breast **(d)**, or ovarian tumor cells **(e)** were co-cultivated at a 1:1 ratio with the indicated CAR/ $\alpha\beta6$ -engineered T-cells in the absence of exogenous cytokine, following *ex vivo* expansion and enrichment of CAR T-cells using IL-4. Data show the mean  $\pm$  SD of residual tumor cell viability from 3-12 independent replicates, quantified by MTT assay or by measuring luciferase activity at 24-72h. At each time-point, percentage cell survival has been expressed relative to untreated tumor cells (set at 100% viability). H – high; I – intermediate; L- low; M – minimal/negative expression of  $\alpha\beta6$ .

**Figure 3 Production of IL-2 by  $\alpha\beta6$  re-targeted CAR T-cells.** Firefly luciferase-expressing pancreatic (a), HER2<sup>+</sup> breast (b), luminal breast (c), triple negative breast (d), or ovarian tumor cells (e) were co-cultivated at a 1:1 ratio with the indicated CAR/4 $\alpha\beta$ -engineered T-cells in the absence of exogenous cytokine, following *ex vivo* expansion and enrichment of CAR T-cells using IL-4. Supernatant was harvested at each time-point and analyzed for IL-2. Data shows the mean  $\pm$  SD of 3-6 independent replicates.

**Figure 4 Relationship between intensity of  $\alpha\beta6$  integrin expression by tumor cells and effector function of CAR T-cells.** Expression of  $\alpha\beta6$  was determined by flow cytometry and then expressed as geometric mean fluorescence intensity (MFI), averaged over 2-8 independent experiments. Relationship between MFI of  $\alpha\beta6$  on tumor cells and % tumor cell viability in cytotoxicity assays (a), release of IL-2 (b) and release of IFN- $\gamma$  (c) by A20-28z/4 $\alpha\beta$  CAR T-cells are depicted graphically, together with Pearson *r* correlation co-efficient and *p* (significance) values for each time-point and effector parameter.

**Figure 5 *In vivo* anti-tumor activity of  $\alpha\beta6$  re-targeted CAR T-cells against SKOV-3 ovarian tumor xenografts.** (a) T-cells were co-transduced with retroviral vectors encoding for rluc/GFP and A20-28z/4 $\alpha\beta$  or the A20-Tr/4 $\alpha\beta$  truncated control. After culture for 12 days in IL-4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. (b) Mice were injected i.p. with 1 x 10<sup>6</sup> SKOV-3-ffluc cells and tumors were allowed to establish for 21 days before i.p. treatment with 10 x 10<sup>6</sup> of the indicated gene-modified T-cells. Bioluminescence imaging using d-luciferin (substrate for ffluc) was used to monitor tumor

status. (c) Data show the mean  $\pm$  SD of tumor-derived total flux (n=5-8 mice per group). Control mice received PBS. The arrow indicates the day of treatment with CAR T-cells. The inset shows initial tumor regression on a log scale. \*\*  $p<0.01$ ; \*\*\*  $p<0.001$  (red – comparing A20-28z v PBS; black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of CAR T-cells. Data show the mean  $\pm$  SD of 5-8 mice/group. The arrow indicates the day of treatment with CAR T-cells.

**Figure 6 *In vivo* anti-tumor activity of  $\alpha v\beta 6$  re-targeted CAR T-cells against BxPC3 PDAC xenografts.** (a) T-cells were co-transduced with retroviral vectors encoding for rluc/GFP and A20-28z/4 $\alpha\beta$  or the A20-Tr/4 $\alpha\beta$  truncated control. After culture for 12 days in IL-4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. (b) Mice were injected i.p. with  $2 \times 10^6$  BxPC3-ffluc/tdTom cells and tumors were allowed to establish for 14 days before i.p. treatment with  $10 \times 10^6$  of the indicated gene-modified T-cells. Bioluminescence imaging using d-luciferin (substrate for ffluc) was used to monitor tumor status. (c) Data show the mean  $\pm$  SD of tumor-derived total flux (n=5-8 mice per group). Control mice received PBS. The arrow indicates the day of treatment with CAR T-cells. The inset shows initial tumor regression on a log scale \*  $p<0.02$ ; \*\*  $p<0.004$ ; \*\*\*  $p<0.0001$  (red – comparing A20-28z v PBS; black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of CAR T-cells. Data show the mean  $\pm$  SD % body weight relative to pre-treatment of 5-8 mice/group. The arrow indicates the day of treatment with CAR T-cells.

**Figure 7 *In vivo* anti-tumor activity of  $\alpha v\beta 6$  re-targeted CAR T-cells against MDA-MB-468 breast cancer xenografts.** (a) T-cells were co-transduced with retroviral vectors encoding for rluc/GFP together with A20-28z/4 $\alpha\beta$  or the truncated control, A20-Tr/4 $\alpha\beta$ . After culture for 12 days in IL-4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. (b) Mice were injected i.p. with  $2 \times 10^6$  MDA-MB468-ffluc cells and tumors were allowed to establish for 42 days before i.p. treatment with  $15 \times 10^6$  of the indicated gene-modified T-cells. Bioluminescence imaging using d-luciferin (substrate for ffluc) was used to monitor tumor status. (c) Data show the mean  $\pm$  SD of tumor-derived total flux (n=5 mice per group). Control mice received PBS. The arrow indicates the day of treatment with CAR T-cells. The inset shows initial tumor regression on a log scale \*\*  $p < 0.003$ ; \*\*\*  $p < 0.0003$  (red – comparing A20-28z v PBS; black – comparing A20-28z v A20-Tr). (d) Mice were weighed weekly to assess toxicity of CAR T-cells. Data show the mean  $\pm$  SD % body weight relative to pre-treatment of 5 mice/group. The arrow indicates the day of treatment with CAR T-cells.

**Figure 8 Imaging of anti-tumor activity and persistence of  $\alpha v\beta 6$  re-targeted CAR T-cells in SCID Beige mice with Panc0403 PDAC xenografts.** (a) T-cells were co-transduced with retroviral vectors encoding for rluc/GFP together with A20-28z/4 $\alpha\beta$  or the truncated control, A20-Tr/4 $\alpha\beta$ . After culture for 12 days in IL-4, cells were analyzed by flow cytometry. 9e10 detects a myc epitope tag in the CAR ectodomain. SSC – side scatter. Quadrants were set using untransduced T-cells cultured in IL-2. (b) Mice were injected i.p. with  $2 \times 10^6$  Panc0403-ffluc cells and tumors were allowed to establish for 14 days before i.p. treatment with  $10 \times 10^6$  of the indicated gene-modified T-cells or PBS as control (arrowed). Bioluminescence imaging using d-



luciferin (substrate for ffluc) was used to monitor tumor status. Data show the mean  $\pm$  SEM of tumor-derived total flux (n=5 mice per group). (c) Mice were weighed weekly to assess toxicity of CAR T-cells. Data show the mean  $\pm$  SEM weight of 5 mice/group. To image T-cells, BLI was performed after administration of coelenterazine at the indicated intervals, commencing 1 hour after T-cell injection. Images of individual mice (d) and pooled BLI data (mean  $\pm$  SEM, n=5) are shown (e).